APIs and Excipients

Curia to Invest $35 Million in Expansions Into Rensselaer, NY Facility

August 19, 2021

Curia plans to expand the site’s commercial capabilities with this move.

Merck KGaA and Telix Partner on Pan-Cancer Clinical Combination Studies

August 19, 2021

Merck KGaA has partnered with Telix Pharmaceuticals to conduct combination clinical studies for cancer therapy.

Biotage Expands Lipid Capacity with New Facility

August 17, 2021

Biotage’s new facility in Cardiff, UK, will produce lipids using large-scale flash purification.

Almac Group and Pila Pharma Sign Manufacturing Agreement

August 13, 2021

Almac Sciences has signed a manufacturing agreement with Pila Pharma for the production of the API XEN-D0501.

KGI Team Adapts Vaccine Development Work to Address COVID-19

August 12, 2021

A research team at the Keck Graduate Institute will work to adapt its decade-long low-cost vaccine R&D for developing countries into a COVID-19 vaccine.

FDA Approves AstraZeneca’s Lupus mAb, Saphnelo

August 03, 2021

FDA has approved AstraZeneca’s Saphnelo, a type I interferon receptor antibody for treating systemic lupus erythematosus.

FDA Accepts Genentech’s Application for Bispecific Antibody to Treat Eye Diseases

August 03, 2021

FDA has accepted Genetech’s BLA for faricimab, a bispecific antibody in development for treating wet age-related macular degeneration and diabetic macular edema.

EC Makes Supply Agreement with GSK and Vir Biotechnology for mAb COVID-19 Treatment

August 03, 2021

The European Commission has entered into a supply agreement with GlaxoSmithKline and Vir Biotechnology for up to 220,000 doses of sotrovimab, an investigational mAb for treating COVID-19.

A Digital Supply Chain Helps Ensure API Quality

August 03, 2021

Data sharing facilitates traceability, transparency, and accuracy while driving efficiencies and boosting quality of active pharmaceutical ingredients.

Byondis and Glycotope Partner on Discovery and Development of Glyco-Epitope-Targeting Antibodies

July 29, 2021

Byondis and Glycotope have formed an agreement to discover and develop antibodies that target specific glyco-epitopes.